Search research articles
Contact Us
Filters
Showing results (11-20 of 51) with videos related to
Page
of 6
Sort By:
American Journal of Cancer Research
|
January 29, 2015
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers
Nandini Dey, Brian Leyland-Jones, Pradip De
Cancers
|
March 25, 2022
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
Pradip De, Jennifer Aske, Raed Sulaiman, et al.
International Journal of Molecular Sciences
|
June 24, 2022
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Nischal Koirala, Nandini Dey, Jennifer Aske, et al.
American Journal of Cancer Research
|
May 6, 2020
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies
Jordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, et al.
Current Drug Targets
|
September 15, 2012
Targeting basal-like breast cancers
Nandini Dey, Brian R Smith, B Leyland-Jones
American Journal of Cancer Research
|
April 18, 2013
Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules
De Pradip, Mark Bouzyk, Nandini Dey, et al.
Oncotarget
|
July 13, 2014
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands
Pradip De, Jennifer Carlson, Brian Leyland-Jones, et al.
Cancer Treatment Reviews
|
April 4, 2017
Mutation matters in precision medicine: A future to believe in
Nandini Dey, Casey Williams, Brian Leyland-Jones, et al.
Cancer Treatment Reviews
|
January 29, 2013
Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope
Pradip De, Keith Miskimins, Nandini Dey, et al.
South Dakota Medicine : the Journal of the South Dakota State Medical Association
|
November 1, 2017
Promise of Precision Medicine in Cancers: Lessons Learned
Nandini Dey, Casey Williams, Brian Leyland-Jones, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 51) with videos related to
Sort By:
Page
of 6
American Journal of Cancer Research
|
January 29, 2015
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers
Nandini Dey, Brian Leyland-Jones, Pradip De
Cancers
|
March 25, 2022
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
Pradip De, Jennifer Aske, Raed Sulaiman, et al.
International Journal of Molecular Sciences
|
June 24, 2022
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Nischal Koirala, Nandini Dey, Jennifer Aske, et al.
American Journal of Cancer Research
|
May 6, 2020
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies
Jordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, et al.
Current Drug Targets
|
September 15, 2012
Targeting basal-like breast cancers
Nandini Dey, Brian R Smith, B Leyland-Jones
American Journal of Cancer Research
|
April 18, 2013
Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules
De Pradip, Mark Bouzyk, Nandini Dey, et al.
Oncotarget
|
July 13, 2014
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands
Pradip De, Jennifer Carlson, Brian Leyland-Jones, et al.
Cancer Treatment Reviews
|
April 4, 2017
Mutation matters in precision medicine: A future to believe in
Nandini Dey, Casey Williams, Brian Leyland-Jones, et al.
Cancer Treatment Reviews
|
January 29, 2013
Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope
Pradip De, Keith Miskimins, Nandini Dey, et al.
South Dakota Medicine : the Journal of the South Dakota State Medical Association
|
November 1, 2017
Promise of Precision Medicine in Cancers: Lessons Learned
Nandini Dey, Casey Williams, Brian Leyland-Jones, et al.
Page
of 6